Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 7/20 | 0.66 |
| ▸ | GIPR | P48546 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | DDHD2 | O94830 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | BCR | P11274 | 2/20 | 0.37 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251890 | 0.87 | GCGR (0.63) | GCGRGIPRKCNH2PTGS2DDHD2 | |
| SCHEMBL2252133 | 0.86 | GCGR (0.77) | GCGRGIPRKCNH2PTGS2DDHD2 | |
| SCHEMBL2252928 | 0.82 | GCGR (0.66) | GCGRGIPRDDHD2ABL1BCR | |
| SCHEMBL9071549 | 0.80 | GCGR (1.00) | GCGRGIPRKCNH2 | |
| SCHEMBL2667424 | 0.79 | GCGR (0.78) | GCGRGIPR | |
| SCHEMBL2251280 | 0.77 | GCGR (0.76) | GCGRGIPRSLC5A1 | |
| SCHEMBL2667516 | 0.77 | GCGR (0.73) | GCGRGIPRKCNH2 | |
| SCHEMBL2667892 | 0.77 | GCGR (0.68) | GCGRGIPRKCNH2DDHD2SLC5A1 | |
| SCHEMBL12360076 | 0.77 | GCGR (1.00) | GCGRGIPR | |
| SCHEMBL2250289 | 0.69 | GCGR (0.63) | GCGRGIPRDDHD2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989475-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1590336-B1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090215825-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2009-08-27 | — | — | US | disclosed |
| US-7572922-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060084681-A1 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2006-04-20 | — | — | US | disclosed |
| EP-1590336-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069158-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215825-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GLP1R, GCGR, GPR119 | GCGR 2/4885GIPR 4/4885KCNH2 1610/4885 |
| US-20060084681-A1 | Substituted pyrazoles, compositions containing such compounds and methods of use | GLP1R, GCGR, GPR119 | GCGR 2/4885GIPR 4/4885KCNH2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.